Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Combined With Immunotherapy and Chemotherapy for Pre-treated SCLC With Liver Metastases
NCT07258147Phase 2Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and liver metastasis, sponsored by Sichuan University. Primary endpoint: Objective Response Rate up to 24 months. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)liver metastasis
Beyond the preview
Go deeper on NCT07258147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07258147.